The current three hospital study is only for infants and children up to the age of 12. Assuming the percentage of correct diagnosis by the algorithms is the same or better than in Australia, is this on its own good enough for FDA approval? What about testing on adults? Surely this is at least as important for the total acceptance by the market?
Or am I missing something?
